SCHEMBL14360593

SCHEMBL14360593

Cc1ccccc1C1(OCCCCOCc2ccccc2)CN(C(=O)O)C1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TEAD3 Q99594 2/20 0.43
EPHX2 P34913 2/20 0.42
MC1R Q01726 7/20 0.39
MC4R P32245 6/20 0.39
GBA1 P04062 3/20 0.37
UGCG Q16739 3/20 0.37
GBA2 Q9HCG7 3/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
NAAA Q02083 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 1/20 0.35
GAA P10253 1/20 0.35
KMT2A Q03164 1/20 0.35
SPHK1 Q9NYA1 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14360193 0.87 L3MBTL1 (0.44) TEAD3EPHX2MC1RMC4RL3MBTL1
SCHEMBL14360222 0.79 MC1R (0.61) MC1RMC4RL3MBTL1TDP1KMT2A
Trifluoroacetic Acid SCHEMBL14360485 0.78 L3MBTL1 (0.39) TEAD3EPHX2L3MBTL1
Trifluoroacetic Acid SCHEMBL14360092 0.77 MC1R (0.48) MC1RMC4RL3MBTL1TDP1
SCHEMBL1310964 0.74 APP (0.37) MC1RMC4R
SCHEMBL2640223 0.66 TSHR (0.70) EPHX2GBA1UGCGGBA2L3MBTL1
SCHEMBL22577745 0.65 EPHX2 (0.44) TEAD3EPHX2L3MBTL1NAAAMEN1
SCHEMBL15956728 0.64 TEAD3 (0.46) TEAD3GBA1UGCGGBA2NAAA
SCHEMBL17402500 0.64 EPHX2 (0.52) TEAD3EPHX2L3MBTL1NAAATDP1
SCHEMBL9011624 0.64 TSHR (0.67) EPHX2GBA1UGCGGBA2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9981952-B2 Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-05-29 US disclosed
EP-2726478-B1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2017-01-11 EP disclosed
US-20160237065-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-08-18 US disclosed
US-9353083-B2 Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2016-05-31 US disclosed
US-20140228342-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2014-08-14 US disclosed
EP-2726478-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS Galderma Research & Development (FR) 2014-05-07 EP disclosed
WO-2013001030-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2013-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237065-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS MC1R, MCHR1, MCHR2 TEAD3 3731/4885EPHX2 1347/4885MC1R 1/4885
US-20140228342-A1 OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS MC1R, MCHR1, MCHR2 TEAD3 4064/4885EPHX2 1681/4885MC1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.